StockData

Nuvation Bio vs UroGen Pharma

NUVB and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NUVB and URGN compare

Nuvation Bio and UroGen Pharma are about the same size, with market caps of $1.4B and $1.5B.

Nuvation Bio grew revenue faster over the last twelve months (1084% versus 100% for UroGen Pharma).

UroGen Pharma keeps more of each dollar of sales as profit, with a net margin of −51.7% compared with −88.2% at Nuvation Bio.

UroGen Pharma scores higher on the StockData Score (6 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNUVBURGN
Size and price
Market cap$1.4B$1.5B
Share price$3.90$29.87
Change, 1 year−19.8%25.7%
Change, 5 years−52.3%146%
Beta (5Y)1.772.73
Employees298291
StockData Score
Total score46 (better)
Valuation score00
Growth score13 (better)
Performance score12 (better)
Health score2 (better)1
Dividend score00
Valuation
P/S8.1×7.7× (better)
P/B5.4×–
FCF yield–−10.9%
Fair value$1.89–
Margin of safety−107%–
Growth
Revenue growth (TTM)1084% (better)100%
Revenue growth, 5Y average–56.2%
Profitability
Gross margin–90.8%
Operating margin−81.0%−35.3% (better)
Net margin−88.2%−51.7% (better)
FCF margin–−84.3%
Return on equity−47.8%–
Financial health
Debt / equity0.02–
Interest coverage−5.4×–
Current ratio8.37 (better)3.80
Altman Z-score0.12 (better)−2.55
Piotroski F-score4 (better)0
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions66.5%86.8%
Held by insiders24.6%5.6%
Insider net buying, 12 months−$4.5M (better)−$4.5M
Superinvestors holding2–
Short interest, % of float23.4%11.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.